U.S. stocks slipped modestly on Tuesday as Wall Street digested a cooler core inflation print, a heavy dose of bank earnings, and fresh tariff salvos from Washington, leaving the major indexes just a step back from record territory rather than in full retreat. Precious metals held near historic highs and bitcoin hovered around five figures that now look oddly pedestrian next to $4,600 gold, while Treasurys signaled a still-steep but slightly calmer curve as traders looked ahead to this month’s FOMC meeting.
Indexes: gravity with manners
The S&P 500 eased about 0.2% to roughly 6,964, giving back part of early January’s sprint but leaving the benchmark still up about 1.7% year to date. The Dow Jones Industrial Average fared worst, shedding roughly 0.8% to just above 49,100 as a weak reaction to JPMorgan’s (JPM, $310.90, -4.19%) earnings weighed on the blue-chip gauge. The Nasdaq Composite and Russell 2000 both slipped around 0.1%, a genteel pullback that suggests growth and small caps are pausing rather than panicking after strong early-year gains.
Macro: cooler core, hotter politics
- December CPI rose 0.3% with annual core inflation easing toward the Fed’s comfort zone, reinforcing expectations for at least two rate cuts later in 2026 even as officials stay publicly cautious.
- The Treasury yield curve remains positive but relatively flat, with the 10‑year around 4.19% and shorter bills clustered in the mid‑3% range, signaling a market that believes in future easing but not a rapid collapse in growth.
- Trade policy re-entered center stage as President Trump moved to impose 25% tariffs on countries doing business with Iran, a step that could lift effective levies on many Chinese imports toward the mid‑40% range and risk reopening the U.S.–China trade rift just as supply chains were finding their equilibrium.
On fiscal risk, both parties in Washington remain publicly committed to avoiding another government shutdown after last year’s epic standoff, and recent reporting suggests the White House is inclined to sign the latest funding package rather than reprise that drama.
Fed, yields and the road ahead
The Fed’s next two‑day FOMC meeting is scheduled for January 27–28, with a rate decision and press conference due on the 28th and markets currently pricing cuts later in the year rather than this month. Daily rate data show front‑end yields still elevated relative to history, but the long end has backed off its 2025 peaks, leaving the curve modestly upward sloping instead of inverted—a configuration more consistent with slower expansion than imminent recession.
Commodities and crypto: hard assets stay loud
Gold traded near $4,600 an ounce, down marginally on the day but still up more than 70% from a year ago as investors continue to pay handsomely for perceived monetary and political insurance. Silver changed hands around the high‑$80s per ounce after another strong daily gain, extending a meteoric 12‑month advance north of $50. Crude prices were steady to slightly higher, with Brent holding above the low‑$60s and WTI flirting with the $60 mark as traders weigh Middle East risk against softening global growth expectations. Bitcoin hovered near $92,000, consolidating recent gains as listed crypto ETFs showed only modest moves on the session.
Street diary: JPM Healthcare and Lilly’s moment
The 44th Annual J.P. Morgan Healthcare Conference rolled into its second day in San Francisco, turning Union Square hotels into a dense ecosystem of GLP‑1 enthusiasm, oncology pipelines, and hurried coffee line diligence checks. Eli Lilly (LLY, $1,077.19, -.35%) was front and center, with executives using the conference spotlight to underscore the company’s next‑generation obesity pill and its potential global reach. Management indicated the oral obesity therapy remains on track for FDA approval as early as the second quarter and suggested long‑term penetration could reach roughly one‑fifth of the global market, reinforcing the notion that this franchise is still in the early innings rather than the late stages.
Analysts continued to debate valuation, noting that Lilly’s shares—recently trading around the low‑$1,000s—carry a premium multiple even after a powerful run, but momentum remains firmly on the company’s side as obesity and diabetes therapies reshape the profit pool for Big Pharma.
Mega‑cap tech and AI: still the main show
- Taiwan Semiconductor (TSM, $331.21, -.17%): Reports surfaced that Washington is nearing a trade arrangement that would lower U.S. tariffs on Taiwanese goods while encouraging further U.S. fab expansion, underscoring the company’s central role in both geopolitics and GPU supply.
- NVIDIA (NVDA, $185.81, +.47%): Nvidia rose slightly with the broader tech complex, though Bernstein reaffirmed the chip designer as a top pick, arguing that AI spending shows “no signs of deceleration” and that consensus numbers likely remain too low.
- Micron Technology (MU): Micron traded mixed intraday as investors weighed still‑tight memory markets against cyclical fears; the stock remains a favored way to play AI‑driven DRAM and HBM demand, but enthusiasm cooled in step with the Nasdaq.
- Apple (AAPL): Apple shares rose .31% to $261.05 with a reaffirmed “buy” from Bank of America, which highlighted resilient iPhone demand and double‑digit Services growth heading into late‑January earnings; today’s move looked more like profit‑taking than a shift in the fundamental narrative.
- Tesla (TSLA): Tesla declined after Wells Fargo reiterated its underweight rating, warning that the market still prices in near‑perfect robotaxi execution even as questions persist around the safety of a vision‑only approach.
- Broadcom (AVGO): Broadcom rose modestly by .68% to $354.61, but remained well‑bid relative to peers after Bernstein again named it, alongside Nvidia, as a preferred AI infrastructure play, citing still‑attractive valuation versus growth prospects.
- Meta Platforms (META): Meta eased by 1.69% to $631.09 despite a reiterated overweight and a nearly $800 price target from Wells Fargo, with the Street focused on heavy 2026 capex but ultimately comfortable that higher spending is tied to monetizable AI and engagement initiatives.
- Palantir Technologies (PLTR): Palantir traded choppily as Citi’s recent upgrade and talk of a “supercycle” met lingering concerns over a valuation that still screens expensive even in an AI‑inflated market.finance.
Other notable movers: chips, burgers, mines and more
- Nokia (NOK, $6.52): Nokia shares were little changed, with investors continuing to treat the name as a steady but unspectacular 5G infrastructure story amid uncertain carrier capex trends.
- McDonald’s (MCD): McDonald’s rose .88% to $309.44 to support the Dow despite continued traffic resilience, as rate‑sensitive investors rotated cautiously out of defensive consumer names after a long run of outperformance.
- Rio Tinto Group (RIO): Rio Tinto rose .86%$ to $83.59 even as metal and bulk commodity traders weighed China‑linked tariff uncertainty and slower global industrial activity against still‑tight supplies in key inputs such as copper and iron ore.
- Oracle (ORCL): Oracle traded lower by 1.17% as investors continued to parse its evolving cloud and AI story; the stock remains sensitive to any hint of slower enterprise spending after a strong multiyear re‑rating.
- Intel (INTC): Intel rose a whopping 7.33% to $47.29 as Keybanc upgraded shares to Overweight citing advances in its manufacturing business and increased demand for its chips from AI data centers.
- Oklo (OKLO): Advanced nuclear developer Oklo traded with a speculative tone dropping 5.28% to $97.09, reflecting both enthusiasm for small modular reactors in a tighter energy and decarbonization environment and the reality that commercialization is still some distance away.
- Opendoor (OPEN): Opendoor moved lower by 3.56% to $6.77 as higher mortgage rates and cautious housing data continued to weigh on sentiment toward iBuying and housing‑adjacent fintech models.
Deal flow, IPOs and corporate chessboard
Despite a more hospitable backdrop for risk assets, today’s M&A tape was relatively quiet, with no mega‑cap mergers, buyouts, or transformative acquisitions announced that could rival last year’s headline deals. The IPO calendar on the NYSE and Nasdaq likewise remained light on actual pricings for the day, though 2026 is expected to feature a deeper bench of offerings—including potential debuts from high‑profile private names and larger life‑sciences issuers that have been preparing since late 2025. Filings and banker chatter continue to point toward a more “normal” issuance environment, but today offered more groundwork than fireworks.
Policy, shutdown risk and tariffs
The lingering after‑effects of the record 43‑day government shutdown last year remain in focus, but current commentary from both parties and market analysts suggests a shared desire to avoid a repeat as new funding bills move through Congress. Investors are watching closely not because they relish the theater, but because the prior episode temporarily scrambled data releases, disrupted payments, and briefly shifted expectations for Fed policy and Treasury issuance..
On trade, Trump’s move to slap 25% tariffs on any country doing business with Iran adds a fresh variable to the already complex tariff landscape, effectively lifting the minimum rate on many Chinese imports and raising the risk of retaliatory action from Beijing and others. For markets, the immediate impact has been more visible in currency moves and sector‑specific jitters than in broad equity indices, but the episode is a reminder that geopolitics can still upstage valuation models on short notice.
Vista Partners Watchlist Updates
AZIO AI, in conjunction with Azio Corp, a next-generation artificial intelligence infrastructure and high-performance computing platform, today announced it has received a binding purchase order for 256 units of the Nvidia B300’s GPUs, representing a significant advancement towards completion of a major governmental Purchase Order in Southeast Asia, resulting in approximately $107 million in contractual revenue, underscoring the Company’s ability to execute complex, large-scale government and institutional initiatives. The company expects to receive a 30% deposit over the course of the next few weeks. On Jan. 6, Envirotech Vehicles, Inc. (NASDAQ: EVTV, $3.52, +40.24% & 512.17% over the last 5-days) announced that it has entered into an Amended and Restated Letter of Intent (“LOI”) with AZIO AI Corporation (“AZIO AI”), pursuant to which EVTV would acquire 100% of the issued and outstanding equity interests of AZIO AI through a merger transaction.
Modular Medical, Inc. (Nasdaq: MODD., $.4771, +.48%), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.
On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.
On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $8.20, +.99%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”
GeoVax Labs, Inc. (Nasdaq: GOVX, $3.48, -2.52%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.
GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.
GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.
GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.
GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.
Volato Group, Inc. (NYSE American: SOAR, $.58) and M2i Global, Inc. (MTWO, $.0532), a company specializing in the development and execution of a complete global value supply chain for critical minerals, recently announced key developments in its pending all-stock merger with M2i Global, Inc.. Volato has filed the Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), following the SEC’s completion of its review of the initial confidential submission. With the reopening of federal agencies following the recent government shutdown, both companies now anticipate closing the merger in the first quarter of 2026, pending completion of SEC review and shareholder approval.
On Jan. 9, M2i Global and Volato Group announced that they have entered into a strategic collaboration agreement with Australian company Titanium X to advance critical mineral development in the US. This partnership represents a significant move towards enhancing domestic refining capacity and strengthening the critical materials supply chain that underpins US industry and national security. Titanium X and M2i Global will work together on the financing, development and commercialisation of the former’s critical mineral assets. M2i Global will apply its global experience in delivering mineral projects to support these initiatives. The companies are also in talks to conclude an exclusive titanium concentrate supply agreement.
On Jan. 7, M2i Global, Inc. along with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, announced a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security.
Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.
On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”
Volato Group, Inc. announced recently that it has set a preliminary date of February 26, 2026 and preliminary record date of January 17, 2026 for a special meeting of shareholders to vote on the proposed merger with M2i Global, Inc. (MTWO) and related matters. The preliminary meeting date and record date remain subject to applicable regulatory and exchange requirements, including the effectiveness of Volato’s Registration Statement on Form S-4 (File No. 333-292132) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) and the mailing of definitive proxy materials to shareholders. The proposed merger creates a combined company built for scale. M2i Global brings a platform focused on critical minerals and national supply chain resilience, while Volato contributes proven aviation technology, software capability, and an established track record of operational execution. Together, the companies aim to participate in a U.S. critical minerals market estimated at more than $320 billion annually.
Serina Therapeutics (NYSE American: SER, $2.46), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.
On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.
The InterGroup Corporation (NASDAQ: INTG, $31.67, +3.16%) announced today(Jan. 6) that on December 29, 2025, it completed the sale of a non-core 12-unit apartment complex in Los Angeles County for a gross sales price of approximately $4,850,000. InterGroup expects to report a GAAP net gain on sale of approximately $3,509,000, which will be reflected in the Company’s Form 10‑Q for the quarter ended December 31, 2025. The transaction is expected to result in federal and state income tax liability, the amount of which will be determined based on the Company’s final tax position and applicable tax rules.
DoubleVerify Holdings Inc. (DV) closed at $10.87, +.18%. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.
flyExclusive, Inc. (NYSE American: FLYX, $3.85), one of the nation’s largest private jet operators and a certified Part 145 Repair Station, today announced it has signed an authorized dealership agreement with Starlink, becoming a certified dealer and installer for Starlink’s high-speed, low-latency aviation connectivity system.
The Sources
- https://tradingeconomics.com/united-states/government-bond-yield
- https://fred.stlouisfed.org/series/DGS10
- https://www.thestreet.com/latest-news/stock-market-today-jan-13-healthy-december-inflation-bolsters-market-rate-cut-case
- https://www.investopedia.com/dow-jones-today-01132026-11884217
- https://www.wsj.com/livecoverage/stock-market-cpi-today-inflation-01-13-2026
- https://fortune.com/article/current-price-of-gold-01-13-2026/
- https://www.home.saxo/en-gb/content/articles/macro/market-quick-take—13-january-2026-13012026
- https://www.barchart.com/story/news/37026885/how-major-us-stock-indexes-fared-tuesday-1-13-2026
- https://www.barrons.com/articles/stocks-fall-on-jpmorgan-earnings-cpi-fed-rates-277904d9
- https://www.stl.news/us-markets-retreat-from-record-highs-on-jan-13-2026/
- https://wealthinsights.metrobank.com.ph/reuters/treasuries-us-yields-fall-after-inflation-data-matches-expectations/
- https://www.bloomberg.com/news/articles/2026-01-13/us-treasuries-edge-lower-as-traders-await-cpi-inflation-reading
- https://public.com/treasury-yield-curve
- https://www.reuters.com/world/china/trumps-iran-tariff-threat-risks-reopening-china-rift-2026-01-13/
- https://www.youtube.com/watch?v=o16RuudCp7E
- https://www.cnn.com/2026/01/12/business/tariffs-trump-iran
- https://www.fmprc.gov.cn/mfa_eng/xw/fyrbt/202601/t20260113_11812020.html
- https://www.jpmorgan.com/insights/global-research/current-events/government-shutdown
- https://www.nyatep.org/blog/state-and-federal-update-january-13-2026
- https://www.federalreserve.gov/releases/h15/
- https://www.clevelandfed.org/indicators-and-data/yield-curve-and-predicted-gdp-growth
- https://www.federalreserve.gov/newsevents/2026-january.htm
- https://bankingjournal.aba.com/2024/08/fomc-releases-tentative-meeting-schedule-for-2025-2026/
- https://fortune.com/article/current-price-of-silver-1-13-2026/
- https://seekingalpha.com/news/4538715-eli-lilly-obesity-pill-track-for-approval-q2
- https://finance.yahoo.com/video/eli-lilly-cfo-weight-loss-200000803.html
- https://seekingalpha.com/article/4859434-eli-lilly-and-company-lly-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript
- https://finance.yahoo.com/news/novo-nordisk-unseat-eli-lilly-140200691.html
- https://www.marketscreener.com/news/eli-lilly-ceo-says-could-be-thinking-about-guiding-2026-more-broadly-in-a-range-than-we-have-before-ce7e58d8db88f027
- https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/assessing-eli-lilly-lly-valuation-after-strong-share-price-m
- https://finance.yahoo.com/news/eli-lilly-lly-laps-stock-224503924.html
- https://www.cnbc.com/2026/01/12/mondays-biggest-analyst-calls-on-wall-street.html
- https://finance.yahoo.com/news/nvidia-palantir-stocks-wall-street-065000212.html
- https://finance.yahoo.com/news/high-growth-us-tech-stocks-113828032.html
- https://www.nasdaq.com/articles/4-leading-tech-stocks-buy-2026
- https://www.goodwinlaw.com/en/insights/publications/2026/01/insights-lifesciences-cm-preparing-for-your-2026-ipo
- https://money.usnews.com/investing/articles/new-and-upcoming-ipos-in-2026
- https://www.benzinga.com/calendars/m-a
- https://finance.yahoo.com/news/crystal-ball-ipos-dealmaking-shake-120513455.html
- https://www.cmegroup.com/newsletters/excell-with-options-report-from-rich-excell/excell-with-options-report-from-rich-excell-2026-01-13.html
- https://home.treasury.gov/resource-center/data-chart-center/interest-rates/TextView?type=daily_treasury_yield_curve&field_tdr_date_value=2026
- https://www.ustreasuryyieldcurve.com
- https://www.marketbeat.com/originals/eli-lilly-stock-rallies-as-ventyx-deal-calms-wegovy-concerns/
- https://finance.yahoo.com/quote/%5EGSPC/history/
- https://www.cnbc.com/2026/01/12/stock-market-today-live-updates.html
